• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗淀粉样蛋白疗法对阿尔茨海默病有效:为什么需要这么长时间,下一步是什么?

An anti-amyloid therapy works for Alzheimer's disease: why has it taken so long and what is next?

机构信息

Reta Lilla Weston Research Laboratories, UCL Institute of Neurology, London, WC1N 3BG, UK.

Department of Neurodegenerative Disease, UCL Institute of Neurology, London, WC1N 3BG, UK.

出版信息

Brain. 2023 Apr 19;146(4):1240-1242. doi: 10.1093/brain/awad049.

DOI:10.1093/brain/awad049
PMID:36797987
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10115350/
Abstract

Hardy and Mummery discuss the recent positive findings in the clinical trial of lecanemab in early Alzheimer’s disease, and the implications for the amyloid hypothesis. They argue that the results mark a turning point for the Alzheimer’s field, but that taking anti-amyloid therapies into clinical practice will be challenging.

摘要

哈迪和马默里讨论了近期在早期阿尔茨海默病中利斯来单抗临床试验的积极发现,以及对淀粉样蛋白假说的影响。他们认为,这些结果标志着阿尔茨海默病领域的一个转折点,但将抗淀粉样蛋白疗法应用于临床实践将具有挑战性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2f3/10115350/f04ac04f473e/awad049f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2f3/10115350/f04ac04f473e/awad049f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2f3/10115350/f04ac04f473e/awad049f1.jpg

相似文献

1
An anti-amyloid therapy works for Alzheimer's disease: why has it taken so long and what is next?抗淀粉样蛋白疗法对阿尔茨海默病有效:为什么需要这么长时间,下一步是什么?
Brain. 2023 Apr 19;146(4):1240-1242. doi: 10.1093/brain/awad049.
2
Alzheimer's disease: where next for anti-amyloid therapies?阿尔茨海默病:抗淀粉样蛋白疗法的下一步何去何从?
Brain. 2017 Apr 1;140(4):853-855. doi: 10.1093/brain/awx059.
3
Effect of Lecanemab in Early Alzheimer's Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective.《阿尔茨海默病早期 Lecanemab 的疗效:淀粉样蛋白级联假说 2.0 视角下的机制解读》。
J Alzheimers Dis. 2023;93(4):1277-1284. doi: 10.3233/JAD-230164.
4
Amyloid PET: A Questionable Single Primary Surrogate Efficacy Measure on Alzheimer Immunotherapy Trials.淀粉样蛋白 PET:阿尔茨海默病免疫疗法试验中一个有争议的单一主要替代疗效指标。
J Alzheimers Dis. 2022;90(4):1395-1399. doi: 10.3233/JAD-220841.
5
Current study on diagnosis and treatment of Alzheimer's disease by targeting amyloid b-protein.通过靶向淀粉样β蛋白对阿尔茨海默病进行诊断和治疗的当前研究。
Folia Neuropathol. 2023;61(1):8-15. doi: 10.5114/fn.2022.119778.
6
Understanding the Amyloid Hypothesis in Alzheimer's Disease.了解阿尔茨海默病中的淀粉样蛋白假说。
J Alzheimers Dis. 2019;68(2):493-510. doi: 10.3233/JAD-180802.
7
Alzheimer's drugs: Does reducing amyloid work?阿尔茨海默病药物:减少淀粉样蛋白是否有效?
Science. 2021 Oct 29;374(6567):544-545. doi: 10.1126/science.abl8366. Epub 2021 Oct 28.
8
Alzheimer's drugs: Does reducing amyloid work?-Response.阿尔茨海默病药物:减少淀粉样蛋白是否有效?-回应
Science. 2021 Oct 29;374(6567):545-546. doi: 10.1126/science.abm3288. Epub 2021 Oct 28.
9
β-Amyloid Accumulation Slows Earlier than Expected in Preclinical Alzheimer's Disease Patients.在临床前阿尔茨海默病患者中,β-淀粉样蛋白的积累比预期更早减缓。
J Neurosci. 2018 Oct 24;38(43):9123-9125. doi: 10.1523/JNEUROSCI.1592-18.2018.
10
The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes.抗淀粉样蛋白单克隆抗体莱卡奈单抗:16项警示说明。
J Alzheimers Dis. 2023;94(2):497-507. doi: 10.3233/JAD-230099.

引用本文的文献

1
Identifying latent classes of longitudinal change in picture naming in a population-based sample.在一个基于人群的样本中识别图片命名纵向变化的潜在类别。
Aging Clin Exp Res. 2025 Aug 29;37(1):262. doi: 10.1007/s40520-025-03169-3.
2
Alzheimer's Disease: Treatment Challenges for the Future.阿尔茨海默病:未来的治疗挑战
J Neurochem. 2025 Aug;169(8):e70176. doi: 10.1111/jnc.70176.
3
Use of Amyloid Positron-Emission Tomography to Diagnose Alzheimer's Disease in Clinical Practice in South Korea: Expert Recommendations.淀粉样蛋白正电子发射断层扫描在韩国临床实践中用于诊断阿尔茨海默病:专家建议。

本文引用的文献

1
Response to: Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.对《接受lecanemab治疗并接受t-PA治疗中风的患者发生多发性脑出血》的回应
N Engl J Med. 2023 Feb 2;388(5):480. doi: 10.1056/NEJMc2215907. Epub 2023 Jan 4.
2
Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.一名接受lecanemab治疗并因中风接受t-PA治疗的患者发生多处脑出血。
N Engl J Med. 2023 Feb 2;388(5):478-479. doi: 10.1056/NEJMc2215148. Epub 2023 Jan 4.
3
Lecanemab in Early Alzheimer's Disease.
J Clin Neurol. 2025 Jul;21(4):251-264. doi: 10.3988/jcn.2025.0037.
4
Longitudinal tau aggregation, atrophy, and cognitive decline in Alzheimer's disease.阿尔茨海默病中tau蛋白的纵向聚集、萎缩及认知衰退
Alzheimers Dement. 2025 Jul;21(7):e70435. doi: 10.1002/alz.70435.
5
What are the reasons for the repeated failures of clinical trials with anti-amyloid drugs for AD treatment?用于治疗阿尔茨海默病(AD)的抗淀粉样蛋白药物临床试验屡屡失败的原因是什么?
Dement Neuropsychol. 2025 Feb 17;19:e2025E001. doi: 10.1590/1980-5764-DN-2025-E001. eCollection 2025.
6
Behavioural pharmacology predicts disrupted signalling pathways and candidate therapeutics from zebrafish mutants of Alzheimer's disease risk genes.行为药理学从阿尔茨海默病风险基因的斑马鱼突变体中预测信号通路的破坏和候选治疗方法。
Elife. 2025 Feb 17;13:RP96839. doi: 10.7554/eLife.96839.
7
Evaluating clinical meaningfulness of anti-β-amyloid therapies amidst amyloid-related imaging abnormalities concern in Alzheimer's disease.在阿尔茨海默病中存在淀粉样蛋白相关成像异常问题的情况下,评估抗β-淀粉样蛋白疗法的临床意义。
Brain Commun. 2024 Dec 3;6(6):fcae435. doi: 10.1093/braincomms/fcae435. eCollection 2024.
8
White matter hyperintensity on MRI and plasma Aβ42/40 ratio additively increase the risk of cognitive impairment in hypertensive adults.MRI 上的脑白质高信号和血浆 Aβ42/40 比值相加会增加高血压成年人认知障碍的风险。
Alzheimers Dement. 2024 Oct;20(10):6810-6819. doi: 10.1002/alz.14126. Epub 2024 Sep 4.
9
It's good to know what to BACE the specificity of your inhibitors on.了解针对抑制剂特异性的 BACE 很重要。
J Clin Invest. 2024 Aug 15;134(16):e183677. doi: 10.1172/JCI183677.
10
Development of the Brazilian version of the Mini-Addenbrooke Cognitive Examination (M-ACE BR) to screen for cognitive impairment in older adults.巴西版简易认知评估量表(M-ACE BR)的开发,用于筛查老年人的认知障碍。
Arq Neuropsiquiatr. 2024 Aug;82(8):1-9. doi: 10.1055/s-0044-1788585. Epub 2024 Aug 8.
早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
4
Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.仑卡奈单抗、阿杜卡玛单抗和加内替单抗——对不同形式的淀粉样蛋白-β的结合谱可能解释了阿尔茨海默病临床试验中的疗效和副作用。
Neurotherapeutics. 2023 Jan;20(1):195-206. doi: 10.1007/s13311-022-01308-6. Epub 2022 Oct 17.
5
Alzheimer disease neuropathology in a patient previously treated with aducanumab.阿杜卡努单抗治疗后的阿尔茨海默病患者的神经病理学。
Acta Neuropathol. 2022 Jul;144(1):143-153. doi: 10.1007/s00401-022-02433-4. Epub 2022 May 17.
6
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.两项早期阿尔茨海默病中阿杜卡努单抗的随机 3 期研究。
J Prev Alzheimers Dis. 2022;9(2):197-210. doi: 10.14283/jpad.2022.30.
7
Blood biomarkers for Alzheimer's disease and related disorders.阿尔茨海默病及相关疾病的血液生物标志物。
Acta Neurol Scand. 2022 Jul;146(1):51-55. doi: 10.1111/ane.13628. Epub 2022 Apr 25.
8
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics.阿尔茨海默病中的淀粉样蛋白假说:新疗法的新见解。
Nat Rev Drug Discov. 2022 Apr;21(4):306-318. doi: 10.1038/s41573-022-00391-w. Epub 2022 Feb 17.
9
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.用于阿尔茨海默病的血液生物标志物:迈向临床应用
Lancet Neurol. 2022 Jan;21(1):66-77. doi: 10.1016/S1474-4422(21)00361-6. Epub 2021 Nov 24.
10
Genetic analysis suggests high misassignment rates in clinical Alzheimer's cases and controls.遗传分析表明,在临床阿尔茨海默病病例和对照中存在高错配率。
Neurobiol Aging. 2019 May;77:178-182. doi: 10.1016/j.neurobiolaging.2018.12.002. Epub 2019 Jan 22.